Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2010

Mar 23, 2010

30291_dirs_2010-03-23_f421f903-49c3-4bb2-850f-2beb0ed10054.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2010-03-19

Reporting Person: MULLEN JAMES C (Director, CEO & President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2010-03-19 Common Stock M 287500 $51.85 Acquired 418649 Direct
2010-03-19 Common Stock M 46721 $49.03 Acquired 465370 Direct
2010-03-19 Common Stock S 334221 $59.9721 Disposed 131149 Direct
2010-03-22 Common Stock M 106279 $49.03 Acquired 237428 Direct
2010-03-22 Common Stock S 106279 $59.9528 Disposed 131149 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2010-03-19 Non-qualified Stock Option (Right to Buy) $51.85 M 287500 Disposed 2010-06-16 Common Stock (287500) Direct
2010-03-19 Non-qualified Stock Option (Right to Buy) $49.03 M 46721 Disposed 2011-12-14 Common Stock (46721) Direct
2010-03-22 Non-qualified Stock Option (Right to Buy) $49.03 M 106279 Disposed 2011-12-14 Common Stock (106279) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 75000 Indirect

Footnotes

F1: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.

F3: This represents the weighted average price for shares sold at a range between $59.95 (low) and $60.15 (high).

F4: This represents the weighted average price for shares sold at a range between $59.95 (low) and $59.98 (high).

F5: The stock option became exercisable in seven (7) equal annual installments, commencing one year after the grant date of 06/16/00.

F6: The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/14/01.

F7: Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).